Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth

HOUSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced its forward-looking strategy for the third and fourth quarters of 2026, centered on deepening relationships with clinical trial sponsors and Contract Research Organizations (CROs). Neutra Corp has committed its full resources to the growth and expansion of Neutra Life Sciences, its wholly owned clinical research Site Management Organization (SMO) subsidiary, as the Company's primary strategic priority for the remainder of 2026 and beyond.

Since its formation, Neutra Life Sciences has built the infrastructure required to support a scalable, multi-site clinical research network, including standardized site operating procedures, an expanding investigator base across multiple therapeutic areas, and a consistent track record of regulatory-compliant trial execution. Having moved from early-growth into a stable operating model, the subsidiary is now positioned to pursue broader and more strategic sponsor and CRO partnerships through the remainder of 2026.

"Our focus is singular — growing Neutra Life Sciences into a premier clinical research site network," said Sydney Jim, President and CEO of Neutra Corp. "We have built a strong operational foundation, and now we are accelerating — bringing in new sponsors, deepening CRO partnerships, and expanding our therapeutic area reach across our growing site network."

Q3 & Q4 2026 – Expanding Sponsor and CRO Relationships

With its corporate resources fully aligned behind Neutra Life Sciences, the Company is accelerating its outreach, visibility, and partnership development efforts for the remainder of the year. Neutra Life Sciences is actively expanding its sponsor relationships, pursuing new CRO partnerships, and positioning itself as a dependable, high-performing SMO partner across multiple therapeutic areas.

"We have put in the work to build a site network that sponsors and CROs can depend on," added Sydney Jim. "Q3 and Q4 are about making sure the right people know what we've built. We are placing ourselves in the rooms where those conversations happen, and we are going with the intent to be awarded new trials."

Industry Conference Presence

As part of its Q3 and Q4 outreach strategy, Neutra Life Sciences will attend select industry conferences to strengthen its visibility among sponsors, CROs, and research partners. Confirmed events include, but are not limited to:

SCRS Global Site Solutions Summit - The Society for Clinical Research Sites (SCRS) Global Summit is the premier gathering of clinical research site professionals and industry stakeholders. Neutra Life Sciences will attend to engage with sponsors, CROs, and fellow site operators, showcase its growing multi-site network, and identify new trial and partnership opportunities.